With reference to the subject matter, As per the Regulation 34 of SEBI (LODR) Regulations, 2015, we hereby submits 40th Annual Report of Gennex Laboratories Limited for the Financial Year ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories has filed its 40th Annual Report and AGM Notice for the financial year ended March 31, 2025 with the stock exchanges, as required under SEBI's listing rules. The 40th Annual General Meeting is scheduled for Tuesday, September 30, 2025 at 12:30 PM and will be held through video conferencing. On the financial side, standalone revenue from operations rose about 42% to ₹9,457.79 lakhs while net profit grew nearly 19% to ₹1,403.68 lakhs versus the previous year. On a consolidated basis, revenue jumped around 59% to ₹13,790.30 lakhs and net profit climbed about 38% to ₹1,812.26 lakhs, reflecting strong business growth. Key AGM agenda items include re-appointment of Managing Director Arihant Baid, regularization of newly inducted director Sandeep Kumar Daga, appointment of a new Secretarial Auditor for five years, and ratification of cost auditor remuneration of ₹50,000. Shareholders can vote electronically between September 27-29, 2025 through NSDL, with the cut-off date being September 23, 2025.
The filing shows healthy revenue and profit growth for FY25, which is a positive signal for shareholders, though diluted EPS dipped slightly because of earlier partly-paid preference warrants. Investors should review the full annual report and use the e-voting window to participate in AGM decisions on director appointments and auditor ratification.